Skip to main content
. 2016 Sep 12;17(9):1500. doi: 10.3390/ijms17091500

Figure 2.

Figure 2

(A) Cumulative overall survival stratified by WFA+-M2BP for patients with hepatocellular carcinoma (HCC) (n = 68). The cumulative one-, three- and five-year survival rates were 78.05%, 42.8% and 20.27%, respectively, in patients with WFA+-M2BP ≥ 6.15 COI (n = 41), while 81.02%, 76.97% and 71.47%, respectively, in patients with WFA+-M2BP < 6.15 COI (n = 27) (p = 0.0026); (B) Cumulative overall survival stratified by WFA+-M2BP for patients without HCC (n = 97). The cumulative one-, three- and five-year survival rates were 100%, 87.5% and 77.58%, respectively, in patients with WFA+-M2BP ≥ 6.15 COI (n = 28), while 100%, 98.31% and 94.76%, respectively, in patients with WFA+-M2BP < 6.15 COI (n = 69) (p = 0.0006).